Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-)NET: Update from the CLARINET Open-Label Extension (OLE) Study

#1188

Introduction: In CLARINET, LAN had significant antitumour effects vs placebo (PBO) on metastatic G1/G2 EP-NETs, liver burden ≤ and >25%, and 96% SD prior to LAN.

Aim(s): To characterise LAN antitumour activity further in the OLE.

Materials and methods: Core study (n=204): patients had metastatic well/moderately differentiated non-functioning EP-NETs with Ki-67 <10%, no prior medical therapy within 6 mo, documented PD/SD status, and received LAN/ PBO for 96 wks or until PD (RECIST 1.0) or death. OLE (n=88): patients entered the OLE if they had SD at end of core study or they had PD on PBO during core study; LAN is administered until (further) PD or death (NCT00842348).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: Lanreotide, antitumour effects,